I am Biotech
Science for Life The Biotechnology Innovation Organization (BIO) is the world’s largest biotechnology trade association.
BIO is a 501(c)(6) non-profit organization headquartered in Washington, D.C. We provide advocacy, business development, and communications services for more than 1,100 members worldwide. It is our mission to be the champion of biotechnology and the advocate for our member organizations - both large and small. Our members - many of whom are small emerging companies - are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Our members work every day to improve the human condition by curing the sick, feeding the hungry or developing cleaner, safer and healthier sources of energy.
09/03/2026
At , experts will examine what it means to usher in 21st century access and affordability, with patient-centric policies that reduce barriers, bureaucracy, and delays - so patients can get the treatment they need, when they need it. View
the full agenda: pace.bio.org
50 years of biotechnology - in 50 seconds: kicking off Sickle Cell Awareness Month
Chris Rofidal, Senior Director, Health Policy and Pipeline Strategy at United Therapeutics Corporation, reflects on a milestone the industry once thought impossible: a highly curative gene therapy for sickle cell disease.
Nearly 8 million people in the U.S. live with psoriatic disease. Roughly 600,000 more remain undiagnosed. The National Psoriasis Foundation's research finds cost, side-effect concerns, and negative healthcare experiences keep many from advancing to effective treatment. Bio.News talks with NPF's Katie Southwick about what's needed to close that gap: https://bio.news/health/connecting-more-patients-with-psoriasis-to-the-care-they-need/
FDA's PDUFA VIII commitment letter recommends new efficiencies while leaning into the existing strengths of a system that makes America the world leader in biotech. BIO's lead negotiator breaks down what's in it on Bio.News: https://bio.news/federal-policy/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator/
09/01/2026
Between innovation and the patient sits a system that too often works against both. When middlemen and insurers absorb the savings meant for patients, they squeeze families and undercut the innovators building tomorrow's treatments.
Simplifying the system protects patients and the science fighting to reach them - and keeps America's biotech engine strong.
: www.bio.org/simplify-the-system
Industries built on intellectual property - including biotech - generated $11.4 trillion in U.S. GDP last year, 44% of total private-sector output, according to a new USPTO report. Bio.News breaks down what the data shows about biotech's economic and societal value.
Small and mid-size biotechs, which develop over half of all new drugs, often have no control over what their overseas licensees charge. Bio.News examines why the proposed Globe and Guard pricing models would make it harder for these companies to fund their next innovation. Read more: https://bio.news/bios-view/globe-and-guard-approaches-ignore-the-realities-of-out-licensing-at-small-and-mid-size-biotech-companies-threaten-innovation/
“Within a week, it was like he was a normal kid,” Ben’s mother says.
Karen and Jonathan spent years searching for an answer to what was happening to their son before genetic testing gave them one: LEPR deficiency, caused by a single gene mutation. A clinical trial gave them a path forward.
The science behind that moment took years to develop. For Ben, it took days to work.
.
Watch Ben’s story: https://fightofourlives.com/stories/ben/
50 years of biotech in 50 seconds: In just a handful of decades, American has advanced from targeting symptoms to offering fundamental cures and broader access for millions across the U.S. Nolan Townsend, CEO of Lexeo Therapeutics, reflects on that shift and what it means for the industry’s next chapter.
08/25/2026
Thank you to BIO member company Shionogi Inc. (U.S.) for the opportunity to join its quarterly town hall last week. BIO President & CEO John F. Crowley shared his personal journey as a biotech entrepreneur and rare disease advocate and highlighted the critical role companies like Shionogi play in advancing innovation for patients with infectious and rare diseases.
John also joined Shionogi President & CEO Nathan Mccutcheon and Senior Executive Officer, Senior Vice President, R&D Supervisory Unit John Keller, for a fireside chat on U.S.-Japan collaboration, AI in drug development, and the future of biotech research. Thank you to the entire Shionogi team for the warm welcome, a great trip, and thoughtful conversations.
Click here to claim your Sponsored Listing.
Category
Contact the organization
Telephone
Address
Alerts
Be the first to know and let us send you an email when I am Biotech posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.